efgartigimod alfa   Click here for help

GtoPdb Ligand ID: 9777

Synonyms: ARGX-113 | efgartigimod alfa-fcab | Vyvgart®
Approved drug Immunopharmacology Ligand
efgartigimod alfa is an approved drug (FDA (2021), EMA (2022))
Compound class: Antibody
Comment: Efgartigimod alfa (ARGX-113) is a first-in-class antibody fragment designed for the treatment of patients with severe autoimmune diseases associated with high levels of pathogenic immunoglobulin G (IgG) autoantibodies [6]. It binds to the IgG receptor, major histocompatibility complex class I-like Fc receptor (FcRn, the protein product of the FCGRT gene). Efgartigimod alfa inactivates FcRn's IgG binding ability (the FcRn-IgG interaction normally protects IgG from degradation) thus facilitating accelerated catabolism of native pathogenic autoantibodies [3,5]. The mechanism of this drug action is discussed more comprehensively in Roopenian and Akilesh (2007) [4] and Vaccaro et al. (2005) [7].
Classification Click here for help
Compound class Antibody
Approved drug? Yes (FDA (2021), EMA (2022))
International Nonproprietary Names Click here for help
INN number INN
10455 efgartigimod alfa
Synonyms Click here for help
ARGX-113 | efgartigimod alfa-fcab | Vyvgart®
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 731
Other databases
GtoPdb PubChem SID 354702250
Search PubMed clinical trials efgartigimod alfa
Search PubMed titles efgartigimod alfa
Search PubMed titles/abstracts efgartigimod alfa